Guardant Health CIO sells 4,000 shares at $158.0483

Guardant Health’s chief information officer sold 4,000 GH shares on September 11, 2026 and now directly holds 39,794 shares.

Rhea-AI Filing Summary

Guardant Health, Inc. (GH) reported that Chief Information Officer Kumud Kalia sold 4,000 shares of common stock on September 11, 2026 in an open‑market or private transaction at a weighted average price of $158.0483 per share. After this sale, the officer directly held 39,794 shares of Guardant Health common stock. The sale price reflects multiple individual trades executed between $157.99 and $158.215 per share. No Rule 10b5-1 trading plan is reported for this transaction.

Insider Trade Summary

Net Seller: 4,000 shares

Net Sell 1 txn

Insider Kalia Kumud

Role Chief Information Officer

Sold 4,000 shs ($632K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	4,000	$158.0483	$632K

Holdings After Transaction: Common Stock — 39,794 shares (Direct)

Footnotes (1)

1. F1. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $157.99 to $158.215. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Key Figures

Shares sold: 4,000 shares Weighted average sale price: $158.0483 per share Sale price range: $157.99 to $158.215 per share +2 more

5 metrics

Shares sold 4,000 shares Common stock sale by the Chief Information Officer on September 11, 2026

Weighted average sale price $158.0483 per share Average price for the 4,000 shares of common stock sold

Sale price range $157.99 to $158.215 per share Range of prices for multiple transactions included in the reported sale

Shares held after sale 39,794 shares Direct holdings of Guardant Health common stock by the reporting officer after the transaction

Number of reported transactions 1 transaction Single reported non-derivative sale of common stock

Key Terms

weighted average sales price per share, multiple transactions, price range

3 terms

weighted average sales price per share financial

"Represents the weighted average sales price per share."

multiple transactions financial

"These shares were sold in multiple transactions at prices ranging"

price range financial

"at prices ranging from $157.99 to $158.215."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Guardant Health (GH) disclose in this Form 4?

Guardant Health disclosed that Chief Information Officer Kumud Kalia sold 4,000 shares of common stock on September 11, 2026 in an open‑market or private transaction at a weighted average price of $158.0483 per share.

What price did the Guardant Health (GH) insider receive for the shares sold?

The reported weighted average sales price was $158.0483 per share. The shares were sold in multiple transactions at prices ranging from $157.99 to $158.215 per share.

How many Guardant Health (GH) shares does the insider hold after this sale?

After the reported sale, Chief Information Officer Kumud Kalia directly holds 39,794 shares of Guardant Health common stock.

Was the Guardant Health (GH) insider sale made under a Rule 10b5-1 trading plan?

No. The filing indicates that no Rule 10b5-1 trading plan is associated with this transaction.

What is the role of the reporting person in Guardant Health (GH)?

The reporting person, Kumud Kalia, serves as Chief Information Officer of Guardant Health, Inc., and is therefore an officer of the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 06:12 PM Accepted by SEC EDGAR 09/14/2026 - 06:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kalia Kumud

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Information Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2026		S		4,000	D	$158.0483(1)	39,794	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $157.99 to $158.215. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Kumud Kalia	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)